INSM:NSD-Insmed Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 74.54

Change

0.00 (0.00)%

Market Cap

USD 12.83B

Volume

0.91M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
PCVX Vaxcyte Inc

N/A

USD 14.16B

ETFs Containing INSM

PTH Invesco DWA Healthcare Mo.. 4.07 % 0.60 %

N/A

USD 0.15B
FCUS Pinnacle Focused Opportun.. 3.94 % 0.00 %

N/A

USD 0.03B
CURE:AU ETFS S&P Biotech ETF 2.46 % 0.00 %

N/A

USD 0.04B
LABU Direxion Daily S&P Biotec.. 1.54 % 1.14 %

N/A

USD 0.99B
VTWG Vanguard Russell 2000 Gro.. 0.88 % 0.20 %

N/A

USD 0.99B
VRTGX Vanguard Russell 2000 Gro.. 0.84 % 0.00 %

N/A

USD 1.19B
XRS2:SW Xtrackers Russell 2000 UC.. 0.45 % 0.00 %

N/A

USD 1.37B
VTWO Vanguard Russell 2000 Ind.. 0.44 % 0.15 %

N/A

USD 11.52B
RSSL Global X Funds 0.43 % 0.00 %

N/A

N/A
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.42 % 0.00 %

N/A

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.42 % 0.00 %

N/A

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.42 % 0.00 %

N/A

USD 3.49B
VRTIX Vanguard Russell 2000 Ind.. 0.42 % 0.00 %

N/A

USD 10.02B
ITWO 0.42 % 0.00 %

N/A

N/A
UWM ProShares Ultra Russell20.. 0.29 % 0.95 %

N/A

USD 0.49B
HDG ProShares Hedge Replicati.. 0.07 % 0.95 %

N/A

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

N/A

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

N/A

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

N/A

USD 0.46B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.37B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.37B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.37B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.37B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 3.42B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.62B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9,521.17% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 9,521.17% 91% A- 97% N/A
Trailing 12 Months  
Capital Gain 11,788.36% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 11,788.36% 91% A- 97% N/A
Trailing 5 Years  
Capital Gain 16,264.43% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16,264.43% 94% A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 222.91% 90% A- 96% N/A
Dividend Return 222.91% 90% A- 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,501.73% 10% F 4% F
Risk Adjusted Return 14.84% 74% C 50% F
Market Capitalization 12.83B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.